Century Therapeutics FY2025 net loss $9.6M; $135M placement extends cash into Q1 2029

Century Therapeutics, Inc.

Net loss of $9.6M improved from $126.6M in 2024; collaboration revenue from BMS rose to $109.2M (from $6.6M).
Cash, cash equivalents, and securities $117.1M at Dec 31, 2025; with $135M Jan 2026 placement, runway extended to Q1 2029.
CNTY-813 (T1D beta islet therapy) IND submission expected Q4 2026; initial clinical data anticipated 2H 2027.
CNTY-308 (CD19-targeted CAR-iT) on track for clinical entry in 2026; CARAMEL IST data expected later this year.
Strengthened balance sheet via oversubscribed $135M private placement led by TCGX; new board members appointed.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Century Therapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $109.2 million.

Period: the full year ended December 31, 2025
Revenue: $109.2 million
Result: reported results

Exact text from the filing

first quarter of 2029. · Collaboration Revenue: Collaboration revenue generated through the company’s collaboration, option, and license agreement with Bristol-Myers Squibb was $109.2 million for the year ended December 31, 2025, compared to $6.6 million for the same period in 2024. · Research and Development (R&D) Expenses: R&D expenses were $95.7 million for the

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-026761

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.